Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosis

Molecular Therapy — Oncolytics(2023)10.1016/j.omto.2023.08.008Source: DataRank Database

JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosis is a research paper published in Molecular Therapy — Oncolytics (2023). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.77)OA: goldTopics (30)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Sergio Corrales-Guerrero ORCID,Verónica Castro-Aceituno ORCID,Sindhu Nair ORCID,Daniel C. Maneval ORCID,Curtis A. Monnig

Live enrichment

PubMed:37674628 PMC:PMC10477748 OpenAlex:https://openalex.org/W4385988162

National Cancer Institute

Grant: R01 CA198128-01

National Cancer Institute

Grant: P30CA033572

National Institutes of Health

Grant: 5P30CA033572-27

Developmental Funds

National Institutes of Health

Grant: 3R01CA198128-06S1

Exploiting Caveolae-Dependent Albumin Endocytosis to optimize Therapy in Pancreatic Cancer

National Institutes of Health

FWCI

0.77

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.omto.2023.08.008

publisherhttps://doi.org/10.1016/j.omto.2023.08.008

publisherhttps://api.elsevier.com/content/article/PII:S2372770523000633?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2372770523000633?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37674628

Fields of Study

Caveolin-1 and cellular processesPancreatic and Hepatic Oncology ResearchErythrocyte Function and Pathophysiology03 medical and health sciences0302 clinical medicine

Keywords

GemcitabineProdrugCaveolin 1AlbuminApoptosisPharmacologyBiomarkerViability assayMedicineCancer researchIn vivoPancreatic cancerEndocytosisCancerChemistryInternal medicineBiologyReceptorBiochemistryCaveolin-1Cav-1Jntx-101Neoplasms. Tumors. Oncology. Including cancer and carcinogensOriginal ArticleRC254-282